Donor Bacteria Transplants Could Cure Chronic Bad Breath, UW Trial Finds

Chronic bad breath is not a hygiene failure. For millions of people, it is a stubborn biological problem rooted in microbial imbalance, one that no amount of mouthwash or tongue scraping reliably fixes. Now researchers at the University of Washington School of Dentistry are running what they believe to be the first clinical trial of oral microbiota transplantation (OMT) for refractory halitosis, borrowing a concept that has already transformed treatment for gut infections and applying it to the mouth.

UW Dentistry’s oral microbiota transplantation trial

The UW clinical trial testing oral bacteria transplants is built around a simple premise: if harmful bacteria are causing the problem, replace them with healthier ones. Four transplants have been completed so far, and preliminary evaluations are underway. The procedure works in two stages. First, the recipient undergoes thorough prophylaxis or deep debridement to disrupt the existing biofilm and knock back the odor-causing bacterial population. Then, bacteria collected from a healthy donor are suspended in saline and introduced to the recipient as both a rinse and a concentrated injection along the gumline.

As researcher Alex Pozhitkov put it: “What we’re trying to do is severely disrupt the original bacteria, and then we bring in the new guys to take hold and establish a new biofilm. If we bring enough of the new bacteria and they outcompete the ones that we disrupted, the healthy ones will take over. It’s a numbers game.”

Dr. Alvin Wee framed the core hypothesis more broadly: “We know the oral microbiome can get out of whack. The question is, can you rebalance it?”

Why chronic halitosis is harder to treat than most people think

Bad breath affects a substantial share of the global population, and the psychological toll of chronic halitosis extends well beyond social awkwardness. Research links persistent oral malodor to depressive symptoms, anxiety, reduced self-esteem, and social isolation. A poll cited in the study found that 52% of respondents rated bad breath as the single biggest interpersonal turnoff, yet many sufferers are unaware that anaerobic bacteria, not last night’s garlic bread, are the primary culprit.

Those bacteria accumulate on the tongue and in the periodontal sulcus, the shallow crevice between teeth and gums, where they break down organic matter and release volatile sulfur compounds. Conventional treatments, from antiseptic rinses to tongue cleaning protocols, target the symptoms and reduce bacterial load temporarily. For patients whose halitosis does not respond to standard care, there has been no reliable biological reset until now.

How OMT borrows its logic from gut medicine

The conceptual model for OMT comes directly from fecal microbiota transplantation (FMT), which has become a standard intervention for recurrent Clostridioides difficile infection and other gut dysbioses. The underlying logic is identical: introduce a healthier microbial community to outcompete and displace pathogenic ones. Earlier rat model research on OMT feasibility found that colonization with salivary flora from healthy subjects decreased odor-causing bacteria and reduced breath values in Wistar rats, providing preclinical evidence that the approach can work before it moves to human trials.

Donor selection at UW follows a similar logic to gut transplant protocols. Ideal donors are intimate partners, family members, or trusted friends of the patient. Crucially, every donor undergoes a full periodontal evaluation to confirm a healthy oral microbiome. A healthy periodontium, the tissues supporting the teeth, serves as a proxy for a bacterial community worth transplanting. The donor bacteria are then collected and suspended in a small volume of saline before application.

Open questions about colonization, durability, and measurement

The trial is early, and the limitations are significant. Only four transplants have been completed, and evaluations remain preliminary. The central biological question is whether donor bacteria can successfully colonize the recipient’s mouth and establish a stable, lasting biofilm rather than simply being washed away. Long-term durability is entirely unknown at this stage.

Measurement is also a challenge. Participants currently self-report changes in breath quality at 90 days post-transplant, which introduces obvious subjectivity. More broadly, challenges facing microbiome-based therapies include significant heterogeneity across studies and a lack of long-term follow-up data, issues the UW team will need to address as the trial scales. There is no standardized protocol yet for what a successful OMT outcome looks like, or how to measure microbial colonization in the oral cavity with enough precision to draw firm conclusions.

What a successful trial could mean for patients with refractory halitosis

If the transplants succeed in establishing stable donor microbiomes in recipients, OMT could offer something genuinely new: a treatment that addresses microbial dysbiosis at its root rather than managing its odorous output. That would matter most to the subset of patients for whom conventional therapy has simply not worked, people who have already tried the mouthwashes, the tongue scrapers, and the antibacterial rinses and still live with a condition that carries real social and psychological costs.

The UW team’s framing is appropriately cautious. This is a feasibility trial, not a proof of efficacy, and the researchers are testing a hypothesis rather than announcing a cure. Four completed transplants with self-reported outcomes at 90 days is a starting point, not a finish line. But it is the first human clinical evidence that oral microbiota transplantation is even worth attempting systematically, and that alone makes the trial worth watching as evaluations of the initial cohort come in.

Evidence rating

INVESTIGATIONAL — 55/100

Caveats:

• Only four transplants have been completed; this is a very early-stage pilot with no control group and no published results.
• Outcome data rely entirely on participant self-reporting of breath quality at 90 days — no objective microbiological or organoleptic measurements are described.
• No peer-reviewed publication exists for this trial; the source is a trade news article, not a scientific paper.
• Funding is not disclosed.

This is a trade-press report describing an early-phase clinical pilot (n=4 completed transplants) with no published peer-reviewed data. Outcomes are based solely on participant self-report at 90 days; no control group, blinding, or objective odor measurement is described. The intervention has not been replicated, and preliminary evaluations are still underway.

References

1. Raluca Briceag, Aureliana Caraiane, Gheorghe Raftu, et al. (2023). Emotional and Social Impact of Halitosis on Adolescents and Young Adults: A Systematic Review. Medicina. https://doi.org/10.3390/medicina59030564
2. Zhiqiang Huang, Yongbo Cheng (2024). Oral microbiota transplantation for intra-oral halitosis: a feasibility analysis based on an oral microbiota colonization trial in Wistar rats. BMC Microbiology. https://doi.org/10.1186/s12866-024-03322-4
3. Georgios Passadakis, Chariklia Neophytou, Sotiria Davidopoulou, Konstantinos Papadimitriou (2025). Effectiveness of Probiotics in Managing Oral Halitosis: A Systematic Review of Randomized Controlled Trials. Journal of International Society of Preventive and Community Dentistry. https://doi.org/10.4103/jispcd.jispcd_19_25